Table 3 Overview of validation studies using other than five- or four-stage systems
From: Evaluating the performance of wearable EEG sleep monitoring devices: a meta-analysis approach
Study | Device | # of el.a | El. Position | El. Type | # of part. | Age [years] | Part. | Env. | Nights | Ref. | Epochs | Device scoringb | ACC | κ | SE | SP | PPV | NPV | F1 | MCC | |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Forehead | |||||||||||||||||||||
Headband | |||||||||||||||||||||
Zhang et al. (2024)65 | LANMAO sleep recorder (prototype)65 | 2 | Fp1, Fp2 | Wet | 34 (M: 16, F: 18) | 4.28 ± 1.61 (1-7) days | Healthy | Controlled | 1 | PSG scored by 2 experts according to AASM | N/R | LANMAO proprietary algorithm | OA (mi.) | 0.80c | 0.65c | N/R | N/R | N/R | N/R | 0.77c | N/R |
Wake | 0.87c | 0.64c | N/R | N/R | N/R | N/R | 0.74c | N/R | |||||||||||||
NREM | 0.86c | 0.74c | N/R | N/R | N/R | N/R | 0.80c | N/R | |||||||||||||
REM | 0.81c | 0.63c | N/R | N/R | N/R | N/R | 0.74c | N/R | |||||||||||||
Lucey et al. (2016)67 | X4 Sleep Profiler70 | 2 | AF7, AF8 (Fpz as ref) | Dry | 29 (M: 17, F: 12) | 54 ± 15.7 (25–80) | Sleep disorders | Controlled | 1 | PSG scored by 2 experts according to AASM | 19326 | Manual scoring | OA (mi.) | N/R | 0.67c | N/R | N/R | N/R | N/R | N/R | N/R |
OA (ma.) | 0.90d | N/R | 0.68d | 0.93d | 0.66d | 0.92d | 0.67d | N/R | |||||||||||||
Wake | 0.89c | N/R | 0.21c | 0.96c | 0.29c | 0.93c | 0.72d | N/R | |||||||||||||
N1 | 0.90c | N/R | 0.21c | 0.96c | 0.29c | 0.93c | 0.24d | N/R | |||||||||||||
N2&N3 | 0.88c | N/R | 0.87c | 0.89c | 0.91c | 0.84c | 0.89d | N/R | |||||||||||||
REM | 0.94c | N/R | 0.86c | 0.95c | 0.76c | 0.98c | 0.81d | N/R | |||||||||||||
Ear | |||||||||||||||||||||
In-ear | |||||||||||||||||||||
Nakamura et al. (2017)68 | Prototype developed in Goverdovsky et al. (2016)74, (2017)75 | 4 | 2 per ear | Wet | 4 (M:4, F:0) | 25–36 | Healthy | Controlled | 1 nap | Scalp-EEG scored by an expert according to AASM | 293 | Machine learning (SVM) | OA (mi.) | 0.77 | 0.65 | 0.77 | 0.92 | 0.77 | 0.92 | 0.77 | 0.65 |
OA (ma.) | 0.88 | 0.63 | 0.70 | 0.91 | 0.74 | 0.92 | 0.72 | 0.63 | |||||||||||||
Wake | 0.90 | 0.72 | 0.79 | 0.93 | 0.78 | 0.94 | 0.79 | 0.72 | |||||||||||||
N1 | 0.88 | 0.50 | 0.50 | 0.95 | 0.66 | 0.91 | 0.57 | 0.51 | |||||||||||||
N2 | 0.84 | 0.67 | 0.89 | 0.78 | 0.79 | 0.89 | 0.84 | 0.68 | |||||||||||||
N3 | 0.92 | 0.62 | 0.60 | 0.97 | 0.75 | 0.94 | 0.67 | 0.63 | |||||||||||||
Palo et al. (2024)66 | IDUN Guardian Development Kit89 | 2 | 1 per ear | Dry | 10 | 18–60 | Healthy | Controlled | 1 | PSG scored by 3 experts according to AASM | 4568 | Manual scoring | Wake | N/R | N/R | 0.80c | N/R | 0.84c | N/R | 0.79c | N/R |
NREM | N/R | N/R | 0.95c | N/R | 0.88c | N/R | 0.91c | N/R | |||||||||||||
REM | N/R | N/R | 0.47c | N/R | 0.65c | N/R | 0.53c | N/R |